Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials.

Liu W, Yang X, Huang J.

Int J Endocrinol. 2018 Mar 12;2018:8726046. doi: 10.1155/2018/8726046. eCollection 2018. Review.

2.

Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes.

Tentolouris A, Eleftheriadou I, Tentolouris N.

Ann Transl Med. 2018 Feb;6(3):63. doi: 10.21037/atm.2017.12.28. No abstract available.

3.

Relationship of Glucose Variability With Glycated Hemoglobin and Daily Mean Glucose: A Post Hoc Analysis of Data From 5 Phase 3 Studies.

Luo J, Qu Y, Zhang Q, Chang AM, Jacober SJ.

J Diabetes Sci Technol. 2018 Mar;12(2):325-332. doi: 10.1177/1932296817736315. Epub 2017 Oct 23.

PMID:
29056082
4.

Weight Management in Patients with Type 1 Diabetes and Obesity.

Mottalib A, Kasetty M, Mar JY, Elseaidy T, Ashrafzadeh S, Hamdy O.

Curr Diab Rep. 2017 Aug 23;17(10):92. doi: 10.1007/s11892-017-0918-8. Review.

5.

Prediction of nocturnal hypoglycemia unawareness by fasting glucose levels or post-breakfast glucose fluctuations in patients with type 1 diabetes receiving insulin degludec: A pilot study.

Takahashi H, Nishimura R, Onda Y, Ando K, Tsujino D, Utsunomiya K.

PLoS One. 2017 Jul 6;12(7):e0177283. doi: 10.1371/journal.pone.0177283. eCollection 2017.

6.

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.

Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, Nielsen TSS, Warren M; Group Information; SWITCH 1.

JAMA. 2017 Jul 4;318(1):33-44. doi: 10.1001/jama.2017.7115.

7.

Efficacy and Safety of Insulin Degludec for Hyperglycemia Management in Noncritical Hospitalized Patients with Diabetes: An Observational Study.

Simioni N, Filippi A, Scardapane M, Nicolucci A, Rossi MC, Frison V.

Diabetes Ther. 2017 Aug;8(4):941-946. doi: 10.1007/s13300-017-0271-6. Epub 2017 Jun 5.

8.

United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes.

Rendell M.

Drug Des Devel Ther. 2017 Apr 13;11:1209-1220. doi: 10.2147/DDDT.S132581. eCollection 2017. Review.

9.

Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data.

Kaku K, Wolden ML, Hyllested-Winge J, Nørtoft E.

Diabetes Ther. 2017 Feb;8(1):189-195. doi: 10.1007/s13300-017-0225-z. Epub 2017 Jan 13.

10.

A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes.

King AB, Kuroda A, Matsuhisa M, Hobbs T.

Curr Diab Rep. 2016 Sep;16(9):83. doi: 10.1007/s11892-016-0772-0. Review.

11.

A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).

Shimoda S, Sato M, Sekigami T, Motoshima H, Yoshimura R, Fukuda K, Matsuo Y, Noda H, Okubo M, Ichimori S, Fujisawa K, Fukunaga M, Araki E; Kumamoto Insulin Degludec Observational (KIDUNA) Study Group.

J Diabetes Investig. 2016 Sep;7(5):703-10. doi: 10.1111/jdi.12496. Epub 2016 Mar 19.

12.

Concentrated insulins: the new basal insulins.

Lamos EM, Younk LM, Davis SN.

Ther Clin Risk Manag. 2016 Mar 9;12:389-400. doi: 10.2147/TCRM.S99855. eCollection 2016. Review.

13.

Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.

Elliott L, Fidler C, Ditchfield A, Stissing T.

Diabetes Ther. 2016 Mar;7(1):45-60. doi: 10.1007/s13300-016-0157-z. Epub 2016 Feb 17.

14.

Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus.

Okada M, Okada M, Nishigami J, Yamaaki N, Furukawa K, Ohyama K, Shimada T, Sai Y.

J Pharm Health Care Sci. 2015 Sep 30;1:26. doi: 10.1186/s40780-015-0027-2. eCollection 2015.

15.

Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24-week results from the observational study in routine clinical practice.

Kobuke K, Yoneda M, Nakanishi S, Ohno H, Maeda S, Egusa G.

J Diabetes Investig. 2016 Jan;7(1):94-9. doi: 10.1111/jdi.12373. Epub 2015 Jun 10.

16.
17.

Concepts and clinical use of ultra-long basal insulin.

Eliaschewitz FG, Barreto T.

Diabetol Metab Syndr. 2016 Jan 6;8:2. doi: 10.1186/s13098-015-0117-1. eCollection 2016. Review.

18.

Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials.

Vora J, Seufert J, Solberg H, Kinduryte O, Johansen T, Hollander P.

Diabetes Obes Metab. 2016 Jul;18(7):716-20. doi: 10.1111/dom.12621. Epub 2016 Feb 8.

19.

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).

Matsuhisa M, Koyama M, Cheng X, Takahashi Y, Riddle MC, Bolli GB, Hirose T; EDITION JP 1 study group.

Diabetes Obes Metab. 2016 Apr;18(4):375-83. doi: 10.1111/dom.12619. Epub 2016 Feb 1.

20.

Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus.

Atkin S, Javed Z, Fulcher G.

Ther Adv Chronic Dis. 2015 Nov;6(6):375-88. doi: 10.1177/2040622315608646. Review.

Supplemental Content

Support Center